Helus Pharma Supports Executive Order on Psychedelics

Helus Pharma has expressed strong support for the recent executive order aimed at advancing research and regulatory pathways for psychedelic drugs in treating serious mental health conditions. As a clinical-stage pharmaceutical company, Helus Pharma is committed to developing innovative therapies. This endorsement aligns with the company's strategic focus and highlights the growing acceptance and potential of psychedelic medicine within the healthcare industry. The order is seen as a crucial step towards unlocking new treatment options for patients suffering from debilitating mental health disorders.